Socioeconomic status and disability progression in multiple sclerosis A multinational study

被引:54
|
作者
Harding, Katharine E. [1 ,2 ,3 ]
Wardle, Mark [4 ]
Carruthers, Robert [1 ,2 ]
Robertson, Neil [3 ,4 ]
Zhu, Feng [1 ,2 ]
Kingwell, Elaine [1 ,2 ]
Tremlett, Helen [1 ,2 ]
机构
[1] Univ British Columbia, Fac Med Neurol, Vancouver, BC, Canada
[2] Univ British Columbia, Djavad Mowafaghian Ctr Brain Hlth, Vancouver, BC, Canada
[3] Cardiff Univ, Univ Hosp Cardiff, Inst Psychol Med & Clin Neurosci, Cardiff, S Glam, Wales
[4] Univ Hosp Wales, Helen Durham Ctr Neuroinflammatory Dis, Dept Neurol, Heath Pk, Cardiff, S Glam, Wales
关键词
NATURAL-HISTORY; DEPRIVATION; MORTALITY; SMOKING; RISK; COMORBIDITY; EDUCATION; GRADIENT; DISEASE; LEVEL;
D O I
10.1212/WNL.0000000000007190
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective To examine the association between socioeconomic status (SES) and disability outcomes and progression in multiple sclerosis (MS). Methods Health administrative and MS clinical data were linked for 2 cohorts of patients with MS in British Columbia (Canada) and South East Wales (UK). SES was measured at MS symptom onset (+/- 3 years) based on neighborhood-level average income. The association between SES at MS onset and sustained and confirmed Expanded Disability Status Scale (EDSS) 6.0 and 4.0 and onset of secondary progression of MS (SPMS) were assessed using Cox proportional hazards models. EDSS scores were also examined via linear regression, using generalized estimating equations (GEE) with an exchangeable working correlation. Models were adjusted for onset age, sex, initial disease course, and disease-modifying drug exposure. Random effect models (meta-analysis) were used to combine results from the 2 cohorts. Results A total of 3,113 patients with MS were included (2,069 from Canada; 1,044 from Wales). A higher SES was associated with a lower hazard of reaching EDSS 6.0 (adjusted hazard ratio [aHR] 0.90, 95% confidence interval [CI] 0.89-0.91), EDSS 4.0 (aHR 0.93, 0.88-0.98), and SPMS (aHR 0.94, 0.88-0.99). The direction of findings was similar when all EDSS scores were included (GEE: beta = -0.13, -0.18 to -0.08). Conclusions Lower neighborhood-level SES was associated with a higher risk of disability progression. Reasons for this association are likely to be complex but could include factors amenable to modification, such as lifestyle or comorbidity. Our findings are relevant for planning and development of MS services.
引用
收藏
页码:E1497 / E1506
页数:10
相关论文
共 50 条
  • [31] Contemporary study of multiple sclerosis disability in South East Wales
    Harding, Katharine Elizabeth
    Ingram, Gillian
    Tallantyre, Emma Clare
    Joseph, Fady
    Wardle, Mark
    Pickersgill, Trevor P.
    Willis, Mark D.
    Tomassini, Valentina
    Pearson, Owen Rhys
    Robertson, Neil P.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2023, 94 (04) : 272 - 279
  • [32] Socioeconomic status and disease-modifying therapy prescribing patterns in people with multiple sclerosis
    Reyes, Saul
    Suarez, Sebastian
    Allen-Philbey, Kimberley
    Yildiz, Ozlem
    Mathews, Joela
    Anjorin, Grace
    Edwards, Freya
    Jain, Cherry
    Turner, Benjamin
    Marta, Monica
    Gnanapavan, Sharmilee
    Schmierer, Klaus
    Giovannoni, Gavin
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 41
  • [33] Socioeconomic Trends in Hospitalization for Multiple Sclerosis
    Lad, Shivanand P.
    Chapman, Christopher H.
    Vaninetti, Michael
    Steinman, Lawrence
    Green, Ari
    Boakye, Maxwell
    NEUROEPIDEMIOLOGY, 2010, 35 (02) : 93 - 99
  • [34] Multiple Sclerosis Progressive Courses: A Clinical Cohort Long-Term Disability Progression Study
    Cortesi, Paolo A.
    Fornari, Carla
    Capra, Ruggero
    Cozzolino, Paolo
    Patti, Francesco
    Mantovani, Lorenzo G.
    VALUE IN HEALTH, 2022, 25 (09) : 1489 - 1498
  • [35] Long-term disability and progression in spinal onset multiple sclerosis
    Tiftikcioglu, Bedile Irem
    Ilgezdi, Irem
    Zorlu, Yasar
    Sener, Ufuk
    Tokucoglu, Figen
    ACTA NEUROLOGICA BELGICA, 2018, 118 (02) : 217 - 225
  • [36] Disability Progression in a Clinical Trial of Relapsing-Remitting Multiple Sclerosis
    Rudick, Richard A.
    Lee, Jar-Chi
    Cutter, Gary R.
    Miller, Deborah M.
    Bourdette, Dennis
    Weinstock-Guttman, Bianca
    Hyde, Robert
    Zhang, Hao
    You, Xiaojun
    ARCHIVES OF NEUROLOGY, 2010, 67 (11) : 1329 - 1335
  • [37] Pediatric Multiple Sclerosis in Rio de Janeiro: Secondary Progression and Disability
    Cerqueira Pinto, Simone Cotrim
    Ferreira Vasconcelos, Claudia Cristina
    Kallenbach Aurencao, Juliana Calvet
    Alvarenga, Marcos Papais
    das Gracas Gomes Camargo, Solange Maria
    Santos Thuler, Luiz Claudio
    Alvarenga, Regina Papais
    PEDIATRIC NEUROLOGY, 2019, 94 : 48 - 54
  • [38] Association of Complement Factors With Disability Progression in Primary Progressive Multiple Sclerosis
    Lunemann, Jan D.
    Hegen, Harald
    Villar, Luisa Maria
    Rejdak, Konrad
    Sao-Aviles, Augusto
    Carbonell-Mirabent, Pere
    Sastre-Garriga, Jaume
    Mongay-Ochoa, Neus
    Berek, Klaus
    Martinez-Yelamos, Sergio
    Perez-Miralles, Francisco
    Abdelhak, Ahmed
    Bachhuber, Franziska
    Tumani, Hayrettin
    Lycke, Jan N.
    Rosenstein, Igal
    Alvarez-Lafuente, Roberto
    Castillo-Trivino, Tamara
    Otaegui, David
    Llufriu, Sara
    Blanco, Yolanda
    Sanchez Lopez, Antonio J.
    Garcia Merino, Juan Antonio
    Fissolo, Nicolas
    Gutierrez, Lucia
    Villacieros-Alvarez, Javier
    Monreal, Enric
    Valls-Carbo, Adrian
    Wiendl, Heinz
    Montalban, Xavier
    Comabella, Manuel
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2024, 11 (04):
  • [39] T2 lesions and rate of progression of disability in multiple sclerosis
    Mostert, J. P.
    Koch, M. W.
    Steen, C.
    Heersema, D. J.
    de Groot, J. C.
    De Keyser, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 (12) : 1471 - 1475
  • [40] Lipids in multiple sclerosis: adverse lipid profiles, disability and disease progression
    Tettey, Prudence
    van der Mei, Ingrid A. F.
    CLINICAL LIPIDOLOGY, 2014, 9 (05) : 473 - 475